Moderna CEO confronts challenges for RSV, COVID businesses
2 days ago · Moderna’s stock price has dropped about 60% in the past 12 months. Facing this set of challenges, Moderna in September laid out a plan to cut annual R&D spending by more than 20%, or $1.1 ...
Moderna Stock Soars After First US Bird-Flu Death - Investopedia
1 day ago · Moderna shares jumped more than 10% to lead S&P 500 gainers Tuesday, a day after the first bird-flu death was reported in the U.S. The biotech company is developing a vaccine for H5N1.
Moderna Stock Jumps Amid Bird Flu Vaccine Hope After ... - MSN
Moderna stock jumped Tuesday after the first bird-flu death was reported in the U.S.. Shares were up 10.6% to $47.10 in early afternoon trading, as the benchmark S&P 500 index was down 0.8%.
Moderna, Inc. (MRNA) Latest Stock News & Headlines - Yahoo ...
Dec 31, 2024 · Get the latest Moderna, Inc. (MRNA) stock news and headlines to help you in your trading and investing decisions.
Moderna shares plunge on plans to cut $1.1 billion in costs ...
Sep 12, 2024 · Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline …
Moderna forecasts lower sales next year, shares near four ...
Sep 12, 2024 · Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key products and predicted 2025 sales below its forecast for the current year,...
News Details - Moderna
Mar 26, 2024 · mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222. Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-1083.
Moderna reports surprise profit on higher-than-expected COVID ...
Nov 7, 2024 · Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory...
Moderna Advances Multiple Vaccine Programs to Late-Stage ...
Mar 27, 2024 · Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints. Expects two more Phase 3 readouts in 2024, including combination vaccine against flu and COVID-19, and vaccine against CMV.
Vaccine Stocks Surge: Moderna Jumps 11% as COVID-19 and Flu ...
1 day ago · Tuesday saw bumps in Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and other vaccine producers as worries about rising COVID-19 and flu infections in the United States drove demand for ...